Haben Sie sich noch nicht registriert? Hier kostenlos Ihr Konto eröffnen.
Passwort vergessen? Wir werden Ihnen einen Zurücksetzen Link senden
7 September 2021
Dr. John Stagg, a world-leader in the adenosine pathway, joins Scientific Advisory Board of Tarus Therapeutics, Inc.
27 Mai 2021
Tarus Therapeutics receives clearance from the FDA to initiate clinical trial of TT-4 (A2BR antagonist) in cancer patients
28 April 2021
Tarus Therapeutics seeks to initiate clinical trial of TT-4 (A2BR antagonist) in cancer patients
6 April 2021
Tarus Therapeutics receives clearance from the FDA to initiate clinical trial of TT-10 (A2AR antagonist) in cancer patients
10 März 2021
Tarus Therapeutics seeks to initiate clinical trial of TT-10 (A2AR antagonist) in cancer patients
2 Dezember 2020
Tarus Therapeutics Strengthens its Board of Directors with Appointment of Paolo Pucci